newsfilter
← Latest News
PR Newswire·

PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program

– Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization –– ST-920 is a one-time administered AAV gene therapy for the enzyme